IL-22 promotes the progression of breast cancer through regulating HOXB-AS5

Jiang Rui; Zhao Chunming; Gao Binbin; Shao Na; Wang Shengxi; Song Wei

doi:10.18632/oncotarget.22063

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

IL-22 promotes the progression of breast cancer through regulating HOXB-AS5

Jiang Rui _, Zhao Chunming, Gao Binbin, Shao Na, Wang Shengxi and Song Wei

PDF | HTML | How to cite

Oncotarget. 2017; 8:103601-103612. https://doi.org/10.18632/oncotarget.22063

Metrics: PDF 1534 views | HTML 2721 views | ?

Abstract

Jiang Rui1, Zhao Chunming2, Gao Binbin1, Shao Na1, Wang Shengxi1 and Song Wei1

1Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China

2Department of Opthalmology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China

Correspondence to:

Jiang Rui, email: [email protected]

Keywords: IL-22, HOXB-AS5, breast cancer, PI3K/AKT/mTOR

Received: August 01, 2017 Accepted: September 23, 2017 Published: October 19, 2017

ABSTRACT

Interleukin-22 (IL-22) is a well-known tumor related inflammatory factor that is associated with variety of cancers. HOXB-AS5, a long non-coding RNA located in HOX gene clusters, has been elevated in breast cancer (BC) tissues. Herein, IL-22 and HOXB-AS5 were upregulated in the serum and tissues of BC patients and were associated with clinical stages. Furthermore, we also investigated the effects of IL-22-HOXB-AS5 pathway on progression of BC, and the results suggested that IL-22 and HOXB-AS5 synergistically promoted MDA-MB-231 cell growth, migration and invasion and activated the PI3K-AKT-mTOR pathway. These findings demonstrated that the IL-22-HOXB-AS5-PI3K/AKT functional axes may serve as potential molecule biomarkers for diagnosis and therapy evaluation or targeted therapeutic strategy in BC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22063

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

IL-22 promotes the progression of breast cancer through regulating HOXB-AS5

Abstract